These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37577663)

  • 1. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies.
    Joisa CU; Chen KA; Beville S; Stuhlmiller T; Berginski ME; Okumu D; Golitz BT; Johnson GL; Gomez SM
    bioRxiv; 2023 Aug; ():. PubMed ID: 37577663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined kinome inhibition states are predictive of cancer cell line sensitivity to kinase inhibitor combination therapies.
    Joisa CU; Chen KA; Beville S; Stuhlmiller T; Berginski ME; Okumu D; Golitz BT; East MP; Johnson GL; Gomez SM
    Pac Symp Biocomput; 2024; 29():276-290. PubMed ID: 38160286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated single-dose kinome profiling data is predictive of cancer cell line sensitivity to kinase inhibitors.
    Joisa CU; Chen KA; Berginski ME; Golitz BT; Jenner MR; Herrera Loeza G; Yeh JJ; Gomez SM
    PeerJ; 2023; 11():e16342. PubMed ID: 38025707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance.
    Krayem M; Aftimos P; Najem A; van den Hooven T; van den Berg A; Hovestad-Bijl L; de Wijn R; Hilhorst R; Ruijtenbeek R; Sabbah M; Kerger J; Awada A; Journe F; Ghanem GE
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition.
    East MP; Johnson GL
    J Biol Chem; 2022 Feb; 298(2):101525. PubMed ID: 34958800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.
    Tran TP; Ong E; Hodges AP; Paternostro G; Piermarocchi C
    BMC Syst Biol; 2014 Jun; 8():74. PubMed ID: 24961498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types.
    Berginski ME; Joisa CU; Golitz BT; Gomez SM
    PLoS Comput Biol; 2023 Feb; 19(2):e1010888. PubMed ID: 36809237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines.
    Berginski ME; Jenner MR; Joisa CU; Herrera Loeza G; Golitz BT; Lipner MB; Leary JR; Rashid N; Johnson GL; Yeh JJ; Gomez SM
    PeerJ; 2024; 12():e17797. PubMed ID: 39221276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues.
    Xiao Y; Guo L; Wang Y
    Mol Cell Proteomics; 2014 Apr; 13(4):1065-75. PubMed ID: 24520089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
    Ghosh S; Fan F; Powell RT; Roszik J; Park YS; Stephan C; Sebastian M; Tan L; Sorokin AV; Lorenzi PL; Kopetz S; Ellis LM; Bhattacharya R
    Mol Cancer Ther; 2023 Aug; 22(8):962-975. PubMed ID: 37310170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data.
    Sidorov P; Naulaerts S; Ariey-Bonnet J; Pasquier E; Ballester PJ
    Front Chem; 2019; 7():509. PubMed ID: 31380352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach.
    Ahmad S; He Q; Williams KP; Scott JE
    SLAS Discov; 2020 Sep; 25(8):923-938. PubMed ID: 32441190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
    Xie X; Lee J; Fuson JA; Liu H; Iwase T; Yun K; Margain C; Tripathy D; Ueno NT
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
    Cooper MJ; Cox NJ; Zimmerman EI; Dewar BJ; Duncan JS; Whittle MC; Nguyen TA; Jones LS; Ghose Roy S; Smalley DM; Kuan PF; Richards KL; Christopherson RI; Jin J; Frye SV; Johnson GL; Baldwin AS; Graves LM
    PLoS One; 2013; 8(6):e66755. PubMed ID: 23826126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
    Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.